Session 1: Mechanistic Modeling of PK in Special Population

Chairs: Yuan Chen, Genentech, and Oliver Hatley, Certara UK Limited, Simcyp Division

Keynote Lecture:  Overview of Special Population, Physiology, Proteomics of Enzymes and Transporters
 Jashvant Unadkat, University of Washington, Seattle, Washington, USA

Organ Impairment PBPK
 Tycho Heimbach, Merck & Co., Inc, Rahway, New Jersey, USA

Pediatric PBPK Model
 Wen Lin, Janssen R&D, Spring House, Pennsylvania, USA

Regulatory Perspective on PBPK Modeling of Special Populations
 Ying-hong Wang, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Selected Abstract Presentation: P1. RETROSPECTIVE EVALUATION OF 33 OAT1/3 RENALLY SECRETED DRUGS: IMPLICATIONS FOR PBPK MODELLLNG OF CHRONIC KIDNEY DISEASE
 Shawn Pei Feng Tan, University of Manchester, Manchester, United Kingdom

Selected Abstract Presentation: P2. PHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING (PBBM) TO ANTICIPATE PH-MEDIATED DDI RISKS IN SPECIAL POPULATIONS AND TO INFORM FORMULATION DEVELOPMENT
 Di Wu, Merck & Co., Inc., Rahway, New Jersey, USA

Roundtable Discussion with Speakers